Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 6

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 6
---
 including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement.

5. Effective 1 January 2025, the Group has updated its presentation of Gross Margin. For further details, see Note 1: 'Basis of preparation and accounting policies' in the Notes to the Interim Financial Statements.

6. Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group's financial statements.

Revenue drivers

Table 3: Product Revenue by medicine

|                                  | 9M 2025 |         | % Change |     | Q3 2025 |         | % Change |     |
|                                  |      $m | % Total |   Actual | CER |      $m | % Total |   Actual | CER |
| Tagrisso                         |   5,352 |      12 |       10 |  10 |   1,864 |      12 |       11 |  10 |
| Imfinzi                          |   4,317 |      10 |       25 |  25 |   1,601 |      11 |       33 |  31 |
| Calquence                        |   2,551 |       6 |       10 |  10 |     916 |       6 |       13 |  11 |
| Lynparza                         |   2,401 |       6 |        8 |   7 |     837 |       6 |        7 |   5 |
| Enhertu                          |   1,976 |       5 |       37 |  38 |     714 |       5 |       40 |  39 |
| Zoladex                          |     884 |       2 |        5 |   6 |     296 |       2 |        7 |   6 |
| Truqap                           |     495 |       1 |       85 |  85 |     193 |       1 |       55 |  54 |
| Imjudo                           |     253 |       1 |       22 |  21 |      84 |       1 |       16 |